Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Oct 21, 2019 - Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.
Oct 18, 2019 - During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Oct 18, 2019 - Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.
Oct 17, 2019 - Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Oct 14, 2019 - Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Oct 11, 2019 - Top Research Reports for Toyota, Amgen & TJX
Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.